NOCIL Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹2.8K Cr
NOCIL expects revenue for FY27 to be in the range of Rs 1,400 to Rs 1,600 crores, based on the current pricing environment. Revenue guidance for FY27 is projected between Rs 1,400 to Rs 1,600 crores, reflecting continued growth.
From NOCIL's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹162
Market Cap
₹2.8K Cr
P/E Ratio
40.1
Revenue Rank
Margin Rank
How does NOCIL rank in Chemicals & Petrochemicals?
Compare NOCIL against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
NOCIL — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹330 Cr, net profit ₹17 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →NOCIL expects revenue for FY27 to be in the range of Rs 1,400 to Rs 1,600 crores, based on the current pricing environment.
- →The company targets around 10% volume growth for the full year FY27.
- →EBITDA margin is expected to hover around 10% for FY27, supported by volume growth and operating leverage.
- →Export volumes aim to grow from around 33% currently to approximately 40-45% by FY28-29, indicating an increased focus on international markets.
- →Specialty segment, constituting 15% of the current topline, is expected to increase by an additional 5-10%, reaching around 20-25% of total revenue in 1-2 years.
- →New capacity from the TDQ plant is anticipated to start contributing from Q4 FY27, with ramp-up expected into FY28.
- →Overall volume growth projections remain positive despite transient supply-side challenges and geopolitical uncertainties.
📈 Profitability & Margins
Rank 3🏗️ Capital Expenditure Plans
Yes- →NOCIL is progressing well with a new Rs 130 crore investment in Dahej.
- →The Rs 130 crore investment is on track despite challenges due to the Middle East geopolitical situation.
- →Trial production at the new TDQ plant in Dahej has started, with sample approvals underway.
- →Commercial volumes from the TDQ plant are expected to start trickling in by Q4 FY27 and ramp up more significantly in Q1 FY28.
- →The investment in the TDQ plant aims to reinforce NOCIL's competitive market position.
- →Expansion focus is shifting towards the Specialty segment, expected to increase from the current 15% of revenue by an additional 5-10% over the next 1-2 years.
- →These expansions and specialty focus align with the strategic goal to diversify and grow product portfolio.
💰 Fundraising & Capital Structure
No information- →The transcript and accompanying document do not mention any current or planned fundraising through debt or equity.
- →There is no discussion of new debt issuance or equity offerings during the Q1 FY27 earnings call or in the accompanying notes.
- →Promoter shareholding pledges were briefly mentioned, but the management declined to comment on the reasons or plans related to promoter pledging.
- →The focus is on operational growth, anti-dumping duty benefits, volume increases, specialty segment expansion, and cost control rather than on raising capital.
- →The company emphasizes maintaining prudent financial management but no explicit fundraising plans were disclosed.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were NOCIL Q1 FY27 results?
NOCIL expects revenue for FY27 to be in the range of Rs 1,400 to Rs 1,600 crores, based on the current pricing environment. Revenue guidance for FY27 is projected between Rs 1,400 to Rs 1,600 crores, reflecting continued growth.
What is NOCIL share price analysis?
NOCIL currently shows a below-average growth signal. The stock trades at a P/E of 40.1 with a market cap of ₹2,790 Cr. Investors should review the full earnings analysis for detailed insights.
Is NOCIL planning capital expenditure?
NOCIL is progressing well with a new Rs 130 crore investment in Dahej.
Keep NOCIL on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.